论文部分内容阅读
目的:观察重组人单核细胞趋化蛋白-1(MCP-1)在骨肉瘤化疗过程中的作用。方法:建立裸鼠荷人骨肉瘤动物模型。应用重组人MCP-1和高剂量氨甲碟呤(HD-MTX)分别及联合对其进行治疗,设立空白对照。观察瘤体的生长及病理指标。结果:MCP-1抑制了骨肉瘤体的生长,但效果尚不理想;MTX明显抑制了骨肉瘤体的生长,效果显著,但可出现肿瘤再生长;MCP-1不但增强了HD-MTX对瘤体的抑制作用,而且使肿瘤再生长的时间明显延迟。结论:重组人单核细胞趋化蛋白-1在骨肉瘤进行高剂量氨甲蝶呤化疗过程中可起到显著的增强治疗作用。
Objective: To observe the role of recombinant human monocyte chemotactic protein-1 (MCP-1) in the chemotherapy of osteosarcoma. Methods: To establish a nude mouse model of human osteosarcoma. Application of recombinant human MCP-1 and high-dose methotrexate (HD-MTX), respectively, and their treatment, the establishment of a blank control. Observation of tumor growth and pathological indicators. Results: MCP-1 inhibited the growth of osteosarcoma, but the effect was not satisfactory. MTX significantly inhibited the growth of osteosarcoma with significant effect, but tumor regrowth appeared. MCP-1 not only enhanced the inhibitory effect of HD-MTX on tumor Body inhibitory effect, but also significantly delayed tumor regrowth. Conclusion: Recombinant human monocyte chemotactic protein-1 can significantly enhance the therapeutic effect of high dose methotrexate chemotherapy in osteosarcoma.